Pfizer Inc. reported a 9 percent rise in second-quarter profit, trouncing Wall Street expectations as revenue jumped 58 percent due to favorable currency rates and its mega-acquisition of fellow drugmaker Wyeth last October.
Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year.
Affymetrix, Inc. announced that it will develop and commercialize the Axiom Chinese myDesign Genotyping Array, the first product that provides maximum power for genome-wide association studies specifically on Chinese populations.
Luminex Corporation announced the global launch of MAGPIX, an analytical instrument that is capable of performing up to 50 tests on a single sample and providing nearly 5,000 data points in under an hour.
Telormedix announced the start of a collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) on a pilot study using Telormedix’s adjuvant, TMX-201, in connection with immunization for malaria and Buruli ulcer.
Cornerstone Therapeutics Inc. announced that it has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors.
In patients with non-small cell lung cancer (NSCLC), five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: When can cure be declared with confidence and how long should follow-up examination be continued?
Scientists have obtained the closest look yet of how a gargantuan molecular machine breaks down unwanted proteins in cells, a critical housekeeping chore that helps prevent diseases such as cancer.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer.
The biopharmaceutical company Antisense Pharma announced that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma.
Germany's Bayer AG saw second-quarter net earnings slip by 1.3 percent as a stronger revenue was offset by one-time charges for lawsuits and writing down a cancer drug.
Biotechnology company Amgen Inc. that its second-quarter net income slipped 5 percent, mainly on higher taxes, but the results topped Wall Street expectations.
AstraZeneca PLC doubled its share buyback program after posting strong second quarter results and revealing that a key new drug - its blood thinner Brilinta - has been given a thumbs up by an advisory committee of the U.S. Food and Drug Administration.
Movetis NV has received a conditional offer from a subsidiary of Shire plc, the global specialty biopharmaceutical company, to acquire all outstanding shares and warrants of Movetis NV for €428 million.